Table 1 Comparison of baseline demographics of patients with or without MVI
MVI(+) | MVI(−) | p value | ||
|---|---|---|---|---|
n = 204 | n = 458 | |||
age > 60y | 37(18.1) | 135(29.5) | 0.002 | |
Gender(male/female) | 19/185 | 72/386 | 0.028 | |
Positive HBsAg | 186(91.2) | 390(85.2) | 0.034 | |
Positive HBV-DNA load(>10^3 IU/ml) | 97(47.5) | 203(44.3) | 0.448 | |
AFP(> 400 ng/ml) | 110(53.9) | 179(39.1)) | < 0.001 | |
Differentiation | poor | 109(53.4) | 166(36.2) | < 0.001 |
well-moderate | 95(46.6) | 292(63.8) | ||
Satellite lesion | 49(24.0) | 37(8.1) | < 0.001 | |
Tumor number** | one | 140(68.6) | 367(80.1) | < 0.001 |
two | 27(13.2) | 62(13.5) | ||
more | 37(18.1) | 29(6.3) | ||
Tumor size(cm) | 7.9 ± 4.0 | 6.0 ± 3.3 | < 0.001* | |
Ishak score | 5–6 | 139(68.1) | 285(62.2) | 0.161 |
0–4 | 65(31.9) | 173(37.8) | ||
BCLC classification** | A | 144(70.6)) | 373(81.4) | 0.002 |
B | 60(29.4) | 85(18.6) | ||
Lg10ALT(U/l)) | 1.7 ± 0.3 | 1.6 ± 0.3 | 0.457 | |
Lg10AST(U/l) | 1.7 ± 0.2 | 1.6 ± 0.3 | 0.007 | |
ALB(g/l) | 41.4 ± 4.2 | 41.5 ± 4.4 | 0.928 | |
TBIL(mmol/l) | 15.1 ± 7.2 | 15.1 ± 6.9 | 0.938 | |
PLR | ≥111 | 87(42.6) | 146(31.9) | 0.008 |
< 111 | 117(57.4) | 312(68.1) | ||
NLR | ≥3 | 76(37.3) | 118(25.8) | 0.003 |
< 3 | 128(62.7) | 340(74.2) | ||
Surgery type | extend | 44(21.6) | 95(20.7) | 0.006 |
major | 81(39.7) | 130(28.4) | ||
minor | 79(38.7) | 233(50.9) | ||
Blood transfusion | 22(10.8) | 28(6.1) | 0.039 | |
Recurrence site | intra-hepatic | 142(69.6) | 238(52.0) | < 0.001 |
extra-hepatic | 26(12.7) | 43(9.4) | ||
Recurrence treatments | salvage LT | 1(0.5) | 7(1.5) | < 0.001 |
re-resection | 15(7.4) | 33(7.2) | 0.066 | |
radiofrequency ablation | 9(4.4) | 31(6.8) | < 0.001 | |
TACE | 72(35.3) | 93(20.3) | < 0.001 | |
pallitive therapy | 64(31.4) | 97(21.2) | < 0.001 |